Terms: = Endocrine gland cancer AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
20 results:
1. Combined BRAF and pim1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of pim1: Synergistic effect and metabolic mechanisms.
Xu Q; Wang J; Mao Y; Xuan Z; Yang K; Tang X; Zhu X
Neoplasia; 2024 Jun; 52():100996. PubMed ID: 38593698
[TBL] [Abstract] [Full Text] [Related]
2. AUM302, a novel triple kinase pim/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
[TBL] [Abstract] [Full Text] [Related]
3. Endoscopic versus Nonendoscopic Surgery for Resection of Craniopharyngiomas.
Abiri A; Roman KM; Latif K; Goshtasbi K; Torabi SJ; Lehrich BM; Mohyeldin A; Hsu FPK; Kuan EC
World Neurosurg; 2022 Nov; 167():e629-e638. PubMed ID: 36041722
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA RGMB-AS1 facilitates pancreatic cancer cell proliferation and migration but inhibits cell apoptosis via miR-574-3p/pim3 axis.
Song W; Shi C
Am J Physiol Gastrointest Liver Physiol; 2021 Nov; 321(5):G477-G488. PubMed ID: 34468207
[TBL] [Abstract] [Full Text] [Related]
5. Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating pim1.
Li Q; Jiang C; Wang Y; Wei M; Zheng H; Xu Y; Xu X; Jia F; Liu K; Sun G; Zang J; Mo P
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1477-1489. PubMed ID: 31292669
[TBL] [Abstract] [Full Text] [Related]
6. DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts.
Wegner CS; Hauge A; Simonsen TG; Gaustad JV; Andersen LMK; Rofstad EK
Neoplasia; 2018 Jul; 20(7):734-744. PubMed ID: 29886124
[TBL] [Abstract] [Full Text] [Related]
7. pim-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.
Xu J; Xiong G; Cao Z; Huang H; Wang T; You L; Zhou L; Zheng L; Hu Y; Zhang T; Zhao Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):133. PubMed ID: 27596051
[TBL] [Abstract] [Full Text] [Related]
8. pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells.
Chen XY; Wang Z; Li B; Zhang YJ; Li YY
Biochem Biophys Res Commun; 2016 Apr; 473(1):296-302. PubMed ID: 27016481
[TBL] [Abstract] [Full Text] [Related]
9. MicroRNA‑506 participates in pancreatic cancer pathogenesis by targeting pim3.
Du J; Zheng X; Cai S; Zhu Z; Tan J; Hu B; Huang Z; Jiao H
Mol Med Rep; 2015 Oct; 12(4):5121-6. PubMed ID: 26238203
[TBL] [Abstract] [Full Text] [Related]
10. SGI-1776, an imidazo pyridazine compound, inhibits the proliferation of ovarian cancer cells by inactivating pim-1.
Xie J; Bai J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):649-57. PubMed ID: 25080901
[TBL] [Abstract] [Full Text] [Related]
11. Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy.
Pelizzaro-Rocha KJ; de Jesus MB; Ruela-de-Sousa RR; Nakamura CV; Reis FS; de Fátima A; Ferreira-Halder CV
Biochim Biophys Acta; 2013 Dec; 1833(12):2856-2865. PubMed ID: 23872419
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of oncogenic pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract] [Full Text] [Related]
13. T-18, a stemonamide synthetic intermediate inhibits pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug.
Wang Z; Li XM; Shang K; Zhang P; Wang CF; Xin YH; Zhou L; Li YY
Oncol Rep; 2013 Mar; 29(3):1245-51. PubMed ID: 23314349
[TBL] [Abstract] [Full Text] [Related]
14. IL-6 stimulates STAT3 and pim-1 kinase in pancreatic cancer cell lines.
Block KM; Hanke NT; Maine EA; Baker AF
Pancreas; 2012 Jul; 41(5):773-81. PubMed ID: 22273698
[TBL] [Abstract] [Full Text] [Related]
15. Identification of a phenanthrene derivative as a potent anticancer drug with pim kinase inhibitory activity.
Wang YY; Taniguchi T; Baba T; Li YY; Ishibashi H; Mukaida N
Cancer Sci; 2012 Jan; 103(1):107-15. PubMed ID: 21981263
[TBL] [Abstract] [Full Text] [Related]
16. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
[TBL] [Abstract] [Full Text] [Related]
17. The oncogenic kinase pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
[TBL] [Abstract] [Full Text] [Related]
18. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.
Li YY; Wang YY; Taniguchi T; Kawakami T; Baba T; Ishibashi H; Mukaida N
Int J Cancer; 2010 Jul; 127(2):474-84. PubMed ID: 19921695
[TBL] [Abstract] [Full Text] [Related]
19. [Effect of ginsenoside Rg3 on pim-3 and Bad proteins in human pancreatic cancer cell line PANC-1].
Jian J; Hu ZF; Huang Y
Ai Zheng; 2009 May; 28(5):461-5. PubMed ID: 19624871
[TBL] [Abstract] [Full Text] [Related]
20. pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines.
Li YY; Popivanova BK; Nagai Y; Ishikura H; Fujii C; Mukaida N
Cancer Res; 2006 Jul; 66(13):6741-7. PubMed ID: 16818649
[TBL] [Abstract] [Full Text] [Related]
